MRNS Marinus Pharmaceuticals Inc.

2.31
+0.05  (+2%)
Previous Close 2.26
Open 2.32
Price To Book 5.92
Market Cap 199,817,592
Shares 86,501,122
Volume 1,443,566
Short Ratio
Av. Daily Volume 1,757,506
Stock charts supplied by TradingView

NewsSee all news

  1. Marinus Provides Business Outlook for 2020

    Enrollment on-track for CDKL5 Deficiency Disorder Phase 3 readout Q3 2020 Two additional late-stage clinical trials planned to initiate in 2020 Company presentation and live webcast at 38th Annual J.P. Morgan Global

  2. Marinus Pharmaceuticals to Present at the 38th Annual J.P. Morgan Global Healthcare Conference

    RADNOR, Pa., Jan. 07, 2020 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), (NASDAQ:MRNS) ("Marinus" or "Company"), a pharmaceutical company dedicated to the development of innovative therapeutics to

  3. Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    RADNOR, Pa., Dec. 13, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) (the "Company", "Marinus"), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat

  4. Marinus Pharmaceuticals Announces Closing of $70 Million Public Offering of Common Stock and Concurrent Private Placement Including Full Exercise of Underwriters' Option to Purchase Additional Shares

    RADNOR, Pa., Dec. 13, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), ("Marinus" or the "Company") today announced the closing of an underwritten public offering of 32,200,000 shares of common

  5. Marinus Pharmaceuticals Appoints Elan Ezickson to Board of Directors

    RADNOR, Pa., Dec. 12, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) ("Marinus" or "Company"), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy,

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 trial to be initiated mid-2020.
Ganaxolone
Refractory status epilepticus (RSE)
Phase 2 negative data released July 23, 2019.
Ganaxolone - Magnolia
Postpartum depression
Phase 2 data released June 2016. Primary endpoint not met but intends to advance development
Ganaxolone
Fragile X Syndrome
Phase 3 data did not meet endpoints - June 2016
Ganaxolone
Focal onset seizures
Phase 3 top-line data due 3Q 2020.
Ganaxolone - Marigold
CDKL5 Deficiency Disorder (CDD)
Phase 3 top-line data due 2021.
Ganaxolone (Violet Study)
PCDH19-related epilepsy
Phase 2 trial to be initiated 1H 2020.
Ganaxolone
Tuberous Sclerosis Complex

Latest News

  1. Marinus Provides Business Outlook for 2020

    Enrollment on-track for CDKL5 Deficiency Disorder Phase 3 readout Q3 2020 Two additional late-stage clinical trials planned to initiate in 2020 Company presentation and live webcast at 38th Annual J.P. Morgan Global

  2. Marinus Pharmaceuticals to Present at the 38th Annual J.P. Morgan Global Healthcare Conference

    RADNOR, Pa., Jan. 07, 2020 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), (NASDAQ:MRNS) ("Marinus" or "Company"), a pharmaceutical company dedicated to the development of innovative therapeutics to

  3. Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    RADNOR, Pa., Dec. 13, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) (the "Company", "Marinus"), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat

  4. Marinus Pharmaceuticals Announces Closing of $70 Million Public Offering of Common Stock and Concurrent Private Placement Including Full Exercise of Underwriters' Option to Purchase Additional Shares

    RADNOR, Pa., Dec. 13, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), ("Marinus" or the "Company") today announced the closing of an underwritten public offering of 32,200,000 shares of common

  5. Marinus Pharmaceuticals Appoints Elan Ezickson to Board of Directors

    RADNOR, Pa., Dec. 12, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) ("Marinus" or "Company"), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy,

  6. Marinus Pharmaceuticals Announces Pricing of $65 Million Public Offering of Common Stock and Concurrent Private Placement

    RADNOR, Pa., Dec. 11, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), ("Marinus" or the "Company") today announced the pricing of an underwritten public offering of 28,000,000 shares of common

  7. Marinus Pharmaceuticals Announces Proposed Public Offering of Common Stock and Concurrent Private Placement

    RADNOR, Pa., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), ("Marinus" or the "Company") today announced that it intends to offer and sell shares of its common stock in an underwritten

  8. Marinus Announces Ganaxolone Orphan Epilepsy Program Updates Including Planned Clinical Program in Tuberous Sclerosis Complex

    Initiation of Phase 2 trial evaluating ganaxolone in tuberous sclerosis complex planned for 1H 2020 European Medicines Agency Orphan Drug Designation granted for ganaxolone for the treatment of CDKL5 deficiency disorder

  9. Marinus Presents Additional Data from Ganaxolone Phase 2 Trial in Refractory Status Epilepticus at the American Epilepsy Society Annual Meeting

    100% of evaluable patients in target dose had no relapse during the four-week follow-up period Independent objective EEG seizure analysis confirms target dose Ganaxolone effective regardless of prior AED treatment and

  10. Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    RADNOR, Pa., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) (the "Company", "Marinus"), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat

  11. Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter Financial Results

     Positive Phase 2 IV ganaxolone data in RSE Strong enrollment continues in pivotal CDD study RADNOR, Pa., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company

  12. Marinus Pharmaceuticals Appoints Joe Hulihan, M.D., as Chief Medical Officer

    RADNOR, Pa., Oct. 29, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) ("Marinus" or "Company"), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy,

  13. Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    RADNOR, Pa., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) (the "Company", "Marinus"), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat

  14. Marinus Pharmaceuticals Announces Positive Top-Line Results With Ganaxolone in Phase 2 Refractory Status Epilepticus Trial

    All patients achieved the primary endpoint Target Phase 3 dose identified Preparing for End-of-Phase 2 meeting with FDA Oral platform presentation at Neurocritical Care Society meeting in October Conference call and

  15. Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    RADNOR, Pa, Aug. 23, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) (the "Company", "Marinus"), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat